

Resource Summary Report

Generated by SPARC SAWG on Jul 29, 2026

Alzheimer's Research Forum

RRID:SCR_006416

Type: Tool

Proper Citation

Alzheimer's Research Forum (RRID:SCR_006416)

Resource Information

URL: <http://www.alzforum.org/>

Proper Citation: Alzheimer's Research Forum (RRID:SCR_006416)

Description: A community building portal dedicated to understanding Alzheimer's disease and related disorders, it reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across disciplines.

Abbreviations: ALZForum, ARF

Resource Type: narrative resource, community building portal, disease-related portal, data or information resource, discussion, topical portal, portal

Keywords: alzheimer's disease, human, mouse, community building portal, forum, FASEB list

Related Condition: Alzheimer's disease

Funding: grants ;
individual donations

Availability: Free, Acknowledgement requested

Resource Name: Alzheimer's Research Forum

Resource ID: SCR_006416

Alternate IDs: nif-0000-00095

License URLs: <http://www.alzforum.org/terms-of-use>

Record Creation Time: 20220129T080236+0000

Ratings and Alerts

No rating or validation information has been found for Alzheimer's Research Forum.

No alerts have been found for Alzheimer's Research Forum.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 112 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Hao M, et al. (2025) Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer's disease. Neural regeneration research, 20(2), 424.

Triplett O, et al. (2025) Active Immunization Targeting Amyloid ? for the Treatment of Alzheimer's Disease. Neuro-degenerative diseases, 25(4), 202.

Wu Y, et al. (2025) ND-AMD: A Web-Based Database for Animal Models of Neurological Disease With Analysis Tools. CNS neuroscience & therapeutics, 31(5), e70411.

Forlenza OV, et al. (2025) What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment? Dementia & neuropsychologia, 19, e2025E001.

Naganishi S, et al. (2025) Gene Expression Signatures of Immaturity, Decreased pH, and Neural Hyperexcitation in the Hippocampus of Alzheimer's Disease Model Mice. Neuropsychopharmacology reports, 45(1), e70001.

Kim HB, et al. (2025) Use of Mitochondrial Delayed Luminescence Measurements From Brain Tissue to Optimize Photobiomodulation Parameters in Alzheimer's Disease Mice. Journal of biophotonics, 18(10), e202500151.

Pillai J, et al. (2025) Benchmarking AlphaMissense pathogenicity predictions against APP, PSEN1, and PSEN2 variants of unknown significance. Biochemistry and biophysics reports, 42, 102049.

Chen J, et al. (2024) Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease. Aging and disease, 15(1), 201.

Singh H, et al. (2024) New insights into the therapeutic approaches for the treatment of tauopathies. Neural regeneration research, 19(5), 1020.

Batista AF, et al. (2024) The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis. *International journal of molecular sciences*, 25(2).

Area-Gomez E, et al. (2024) Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis. *Journal of Alzheimer's disease : JAD*, 98(4), 1243.

Chu D, et al. (2024) Tau truncation in the pathogenesis of Alzheimer's disease: a narrative review. *Neural regeneration research*, 19(6), 1221.

Rizzi L, et al. (2024) Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. *Acta neuropathologica communications*, 12(1), 36.

Stellick Bedrejo CA, et al. (2024) Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated. *PloS one*, 19(9), e0307761.

de Boni L, et al. (2024) Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients. *EMBO molecular medicine*, 16(7), 1657.

Gilani N, et al. (2024) Homozygous TREM2 c.549del; p.(Leu184Serfs*5) variant causing Nasu-Hakola disease in three siblings in a consanguineous Iraqi family: Case report and review of literature. *Molecular genetics & genomic medicine*, 12(6), e2476.

Chu J, et al. (2024) Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. *Neural regeneration research*, 19(1), 100.

Zhang Y, et al. (2024) E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease. *Genes & diseases*, 11(2), 1022.

Arber C, et al. (2024) The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated A β 43 and atypical clinical manifestations. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(7), 4717.

Yu HJ, et al. (2023) Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study. *EBioMedicine*, 94, 104665.